Welcome to today's Medical News Today News Alert containing today's medical news headlines for your chosen categories. You will only receive these alerts when new news is available for your chosen categories.
To unsubscribe from our news alerts, or to alter any of your subscription details (name,e-mail address etc) please see
http://www.medicalnewstoday.com/newsalerts.php?changemydetails=y .
----------------------------------------------
** BREAST CANCER News **
New York Times Examines Debate Over Mammography For Women Over 80
http://www.medicalnewstoday.com/articles/114503.php
<BR />The <A href="http://www.nytimes.com/2008/07/08/health/08canc.html?_r=1&oref=slogin" target=_new><CITE>New York Times</CITE></A> on Monday examined the debate among physicians on the value of recommending that women ages 80 and older receive annual mammograms -- a debate that has arisen because of the paucity of data available for this age group because large clinical trials traditionally focused on younger people and excluded the very old.
Herceptin Targets Breast Cancer Stem Cells
http://www.medicalnewstoday.com/articles/114466.php
A gene that is overexpressed in 20 percent of breast cancers increases the number of cancer stem cells, the cells that fuel a tumor's growth and spread, according to a new study from the University of Michigan Comprehensive Cancer Center.
----------------------------------------------
** CANCER / ONCOLOGY News **
Aerosol Toxins From Red Tides May Cause Long-Term Health Threat
http://www.medicalnewstoday.com/articles/114554.php
NOAA scientists reported in the current issue of the journal <i>Environmental Health Perspectives</i> that an algal toxin commonly inhaled in sea spray, attacks and damages DNA in the lungs of laboratory rats.
Introgen To Host Conference Call With Clinical Investigators To Discuss Phase III Data And ADVEXIN Registration Activities
http://www.medicalnewstoday.com/articles/114549.php
Introgen Therapeutics, Inc. (NASDAQ:INGN) announced that it will host a conference call with management and invited clinical experts on Thursday, July 10, 2008 at 3:30 p.m. ET. Introgen management will discuss its recent ADVEXIN regulatory approval filings and phase III clinical data.
In Spite Of Setbacks, Therapeutic Cancer Vaccines Continue To Make Gains - Immune Science Associates Assessment Analyzes Evolving Strategies
http://www.medicalnewstoday.com/articles/114546.php
Efforts to up-regulate the human immune system to recognize and destroy tumor cells with minimal side effects and collateral damage to healthy tissue continue to attract a mixture of optimism and determination from vaccine developers and skepticism from potential Pharma partners.
Minorities, Rural Residents In Maryland Less Likely To Be Cancer Clinical Trial Participants, Study Finds
http://www.medicalnewstoday.com/articles/114532.php
Minorities and rural residents in Maryland are underrepresented in cancer clinical trials and blacks' rate of participation is dropping, according to a study published in the July issue of the <cite>Journal of Clinical Oncology</cite>, the <a href="http://www.
Institute Professor Wins Prestigious Science Award, UK
http://www.medicalnewstoday.com/articles/114514.php
The Institute of Cancer Research's Professor Christopher Marshall FRS has been awarded the Royal Society's prestigious 2008 Buchanan Medal. The medal is in recognition of his outstanding contribution to understanding how cancers develop and identifying major targets for cancer therapeutic treatments.
Merck Serono: Erbitux(R) Phase III Clinical Study In Gastric Cancer Started
http://www.medicalnewstoday.com/articles/114494.php
Merck Serono, a division of Merck KGaA, announced that the first patient has been enrolled into its pivotal Phase III gastric cancer clinical study, EXPAND (Erbitux in combination with Xeloda and cisplatin in advanced esophago-gastric cancer).
Roswell Park Researcher Receives $1.2 Million To Study Cancer Immunology
http://www.medicalnewstoday.com/articles/114478.php
Peter Demant, MD, PhD, Distinguished Member, Department of Molecular and Cellular Biology at Roswell Park Cancer Institute (RPCI), has been awarded a four-year, $1.2 million grant from the National Cancer Institute (NCI) to evaluate how an individual's genes impact his/her immune response to cancer.
AACR Announces New Grant Opportunity For Bladder Cancer Research
http://www.medicalnewstoday.com/articles/114477.php
The <a href="http://www.aacr.org" target="_blank" rel="nofollow"> American Association for Cancer Research </a> is currently accepting applications for grants designed to help drive research advances in the treatment of bladder cancer, the fourth most commonly diagnosed cancer in men and the eighth in women.
Risk Factors Identified For Skin Cancer: Tumor Thickness, Immune Status, Desmoplastic Growth, And Location On The Ear
http://www.medicalnewstoday.com/articles/114282.php
Several specific risk factors have been identified in the recurrence orspreading of cutaneous squamous-cell carcinoma, or skin cancer. Thesefactors, released on July 9, 2008 in <i>The Lancet Oncology</i>,include: a tumor thickness of 6.
----------------------------------------------
** CERVICAL CANCER / HPV VACCINE News **
No news for this category today.
----------------------------------------------
** COLORECTAL CANCER News **
No news for this category today.
----------------------------------------------
** LUNG CANCER News **
Anti-Tobacco Campaign Tests Lung Capacity, Determination And Tobacco Awareness In 'Miley Mania Adventure'
http://www.medicalnewstoday.com/articles/114566.php
Pop culture, anti-tobacco awareness and physical endurance merged last Friday in <a href="http://www.fighttheugly.com/" target="_blank" rel="nofollow">The TRUTH's</a> 'Miley Mania Adventure' in Salt Lake City.
----------------------------------------------
** LYMPHOMA / LEUKEMIA News **
Not The Protein, But Its Location In The Cell, Determines The Onset Of Leukemia
http://www.medicalnewstoday.com/articles/114430.php
Leukemia, or cancer of the bone marrow, strikes some 700 Belgians every year. Scientists are still searching for the cause of many forms of the disease, including T-cell acute lymphoblastic leukemia (T-ALL).
----------------------------------------------
** PROSTATE / PROSTATE CANCER News **
Prostate Cancer Vaccines More Effective With Hormone Therapy
http://www.medicalnewstoday.com/articles/114428.php
Among patients with castration-resistant prostate cancer, the addition of hormone therapy following vaccine treatment improved overall survival compared with either treatment alone or when the vaccine followed hormone treatment, according to recent data published in the July 15 <a href="http://clincancerres.
-------------------------------------------------------------
You are receiving this news alert e-mail because you subscribed via an online form on our web site. If you wish to unsubscribe, please visit
http://www.medicalnewstoday.com/newsalerts.php?changemydetails=y .
No comments:
Post a Comment